OpenAI acquires Orchestra Bio
AI company OpenAI has acquired biotechnology startup Orchestra Bio, bringing it into the company. While the financial terms were not disclosed, the startup’s team and technology will be integrated into OpenAI’s life sciences work.
Orchestra Bio develops AI solutions that support drug discovery processes. Its solutions focus on a range of operational needs, from tracking financial processes to addressing timing issues in clinical research.
The startup develops AI agents to help biotechnology companies streamline operational work in drug discovery. OpenAI said Orchestra Bio’s team and technology will be incorporated into its Rosalind AI model and Rosalind Workbench tool.
OpenAI says it has already gained customers for Rosalind including Moderna and Novo Nordisk.
